Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2007

Open Access 01-12-2007 | Research article

Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a population-based case-control study

Authors: Montserrat Garcia-Closas, Louise A Brinton, Jolanta Lissowska, Douglas Richesson, Mark E Sherman, Neonila Szeszenia-Dabrowska, Beata Peplonska, Robert Welch, Meredith Yeager, Witold Zatonski, Stephen J Chanock

Published in: BMC Cancer | Issue 1/2007

Login to get access

Abstract

Background

The sex hormone-binding globulin (SHBG) is a carrier protein that modulates the bio-availability of serum sex steroid hormones, which may be involved in ovarian cancer. We evaluated whether common genetic variation in SHBG and its 3' neighbor ATP1B2, in linkage disequilibrium, is associated with the risk of epithelial ovarian cancer.

Methods

The study population included 264 women with ovarian carcinoma and 625 controls participating in a population-based case-control study in Poland. Five common single nucleotide polymorphisms (SNPs) in SHGB and five in ATP1B2 were selected to capture most common variation in this region.

Results

None of the SNPs evaluated was significantly associated with ovarian cancer risk, including the putative functional SNPs SHBG D356N (rs6259) and -67G>A 5'UTR (rs1799941). However, our data were consistent with a decreased ovarian cancer risk associated with the variant alleles for these two SNPs, which have been previously associated with increased circulating levels of SHBG.

Conclusion

These data do not support a substantial association between common genetic variation in SHBG and ovarian cancer risk.
Appendix
Available only for authorised users
Literature
1.
Risch HA: Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998, 90: 1774-1786. 10.1093/jnci/90.23.1774.CrossRefPubMed
2.
Lukanova A, Lundin E, Akhmedkhanov A, Micheli A, Rinaldi S, Zeleniuch-Jacquotte A, Lenner P, Muti P, Biessy C, Krogh V, Berrino F, Hallmans G, Riboli E, Kaaks R, Toniolo P: Circulating levels of sex steroid hormones and risk of ovarian cancer. Int J Cancer. 2003, 104: 636-642. 10.1002/ijc.10990.CrossRefPubMed
3.
Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, Comstock GW: Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA. 1995, 274: 1926-1930. 10.1001/jama.274.24.1926.CrossRefPubMed
4.
Selby C: Sex hormone binding globulin: origin, function and clinical significance. Ann Clin Biochem. 1990, 27 ( Pt 6): 532-541.CrossRef
5.
Cousin P, Calemard-Michel L, Lejeune H, Raverot G, Yessaad N, Emptoz-Bonneton A, Morel Y, Pugeat M: Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women. J Clin Endocrinol Metab. 2004, 89: 917-924. 10.1210/jc.2002-021553.CrossRefPubMed
6.
Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PD, Easton DF, Day NE, Ponder BA: Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst. 2004, 96: 936-945.CrossRefPubMed
7.
Haiman CA, Riley SE, Freedman ML, Setiawan VW, Conti DV, Le Marchand L: Common genetic variation in the sex steroid hormone-binding globulin (SHBG) gene and circulating shbg levels among postmenopausal women: the Multiethnic Cohort. J Clin Endocrinol Metab. 2005, 90: 2198-2204. 10.1210/jc.2004-1417.CrossRefPubMed
8.
Langerød A, Burdette L, YM LV, Presswalla S, Gerhadt D, Tarazona-Santos , Garcia- Rossi D, Lønning PE, Kristensen VN, Chanock S: Pattern of genetic variation in the TP53 locus indicates linkage disequilibrium extends across the flanking genes, ATP1B2 and WDR79. 2007
9.
Packer BR, Yeager M, Burdett L, Welch R, Beerman M, Qi L, Sicotte H, Staats B, Acharya M, Crenshaw A, et al: SNP500Cancer: A Public Resource for Sequence Validation, Assay Development, and Frequency Analysis for Genetic Variation in Candidate Genes. Nucl Acids Res. 2006, 34 (Database Issue): D617-D621. 10.1093/nar/gkj151.CrossRef
10.
11.
Webb PM, Green A, Cummings MC, Purdie DM, Walsh MD, Chenevix-Trench G: Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst. 1998, 90: 1729-1734. 10.1093/jnci/90.22.1729.CrossRefPubMed
12.
13.
Schaid DJ: Evaluating associations of haplotypes with traits. Genet Epidemiol. 2004, 27: 348-364. 10.1002/gepi.20037.CrossRefPubMed
14.
15.
Weiss NS, Cook LS, Farrow DC, Rosenblatt KA: Ovarian Cancer. Cancer Epidemiology and Prevention. Edited by: Schottenfeld D, Fraumeni JF. 1996, New York, Oxford University Press, 1040-1057.
Metadata
Title
Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a population-based case-control study
Authors
Montserrat Garcia-Closas
Louise A Brinton
Jolanta Lissowska
Douglas Richesson
Mark E Sherman
Neonila Szeszenia-Dabrowska
Beata Peplonska
Robert Welch
Meredith Yeager
Witold Zatonski
Stephen J Chanock
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2007
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-7-60

Other articles of this Issue 1/2007

BMC Cancer 1/2007 Go to the issue

Debate

Adjuvant breast cancer chemotherapy during late-trimester pregnancy: not quite a standard of care

Research article

Availability and quality of paraffin blocks identified in pathology archives: A multi-institutional study by the Shared Pathology Informatics Network (SPIN)

Research article

Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells

Research article

Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study

Research article

Promotion of breast cancer by β-Hexachlorocyclohexane in MCF10AT1 cells and MMTV-neu mice

Research article

The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits